NEW YORK ( TheStreet) -- It appears we may be challenging Dow 10,000 again this morning. The early reaction to earnings is overwhelmingly positive. Here are the names that are in the news this morning.
A KeyBanc Capital Markets analyst increases his price target on the stock to $221 from $199.
The FDA today authorized Abbott's (ABT) FreeStyle Libre Pro system, which is used to continually monitor diabetic patients' glucose levels.
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.